J Biol Chem, Vol. 274, Issue 34, 23858-23867, August 20, 1999
Differentiation-dependent Suppression of
Platelet-derived Growth Factor Signaling in Cultured Adipocytes*
Scott A.
Summers
,
Eileen L.
Whiteman
§¶,
Han
Cho
**,
Lorraine
Lipfert, and
Morris J.
Birnbaum
From the Howard Hughes Medical Institute, The Cox Institute, the
§ Cell and Molecular Biology Graduate Group, and the
Departments of Biology and Medicine, University of Pennsylvania
Medical School, Philadelphia, Pennsylvania 19104
 |
ABSTRACT |
A critical component of vertebrate
cellular differentiation is the acquisition of sensitivity to a
restricted subset of peptide hormones and growth factors. This accounts
for the unique capability of insulin (and possibly insulin-like growth
factor-1), but not other growth factors, to stimulate glucose uptake
and anabolic metabolism in heart, skeletal muscle, and adipose tissue.
This selectivity is faithfully recapitulated in the cultured adipocyte line, 3T3-L1, which responds to insulin, but not platelet-derived growth factor (PDGF), with increased hexose uptake. The
serine/threonine protein kinases Akt1 and Akt2, which have been
implicated as mediators of insulin-stimulated glucose uptake, as well
as glycogen, lipid, and protein synthesis, were shown to mirror this
selectivity in this tissue culture system. This was particularly
apparent in 3T3-L1 adipocytes overexpressing an epitope-tagged form of
Akt2 in which insulin activated Akt2 10-fold better than PDGF.
Similarly, in 3T3-L1 adipocytes, only insulin stimulated
phosphorylation of Akt's endogenous substrate, GSK-3
. Other
signaling molecules, including phosphatidylinositol 3-kinase, pp70
S6-kinase, mitogen-activated protein kinase, and PHAS-1/4EBP-1, did not
demonstrate this selective responsiveness to insulin but were instead
activated comparably by both insulin and PDGF. Moreover, concurrent
treatment with PDGF and insulin did not diminish activation of
phosphatidylinositol 3-kinase, Akt, or glucose transport, indicating
that PDGF did not simultaneously activate an inhibitory mechanism.
Interestingly, PDGF and insulin comparably stimulated both Akt
isoforms, as well as numerous other signaling molecules, in
undifferentiated 3T3-L1 preadipocytes. Collectively, these data suggest
that differential activation of Akt in adipocytes may contribute to
insulin's exclusive mediation of the metabolic events involved in
glucose metabolism. Moreover, they suggest a novel mechanism by which
differentiation-dependent hormone selectivity is conferred
through the suppression of specific signaling pathways operational in
undifferentiated cell types.
 |
INTRODUCTION |
Under the appropriate conditions, 3T3-L1 fibroblasts differentiate
into cells with an adipocyte phenotype characterized by the
accumulation of triglyceride and increased sensitivity to insulin. In
these differentiated cells, as well as rat and human adipocytes,
insulin accelerates glucose entry by effecting the translocation of
glucose transporter 4 (GLUT4)1 from intracellular
stores to the plasma membrane (1). Subsequently, insulin stimulates
metabolic pathways to promote storage of the incoming glucose as
glycogen or triglyceride. In this capacity, insulin stands apart from
other growth factors, such as platelet-derived growth factor (PDGF),
which activate remarkably similar signaling cascades yet are incapable
of eliciting these metabolic events (2-8). A clear explanation of how
these very similar signaling pathways elaborate such radically
different physiological responses in this differentiated tissue has
remained elusive, although compartmentalization of signaling molecules
has been proposed (9).
Both insulin and PDGF activate their respective tyrosine kinase
receptors to phosphorylate key residues on a "docking protein" or
the receptor, respectively, which recruits multiple adaptor proteins.
Recruited proteins include the GDP exchange factor Son of Sevenless, or
SOS, which activates the Ras/Raf/mitogen-activated protein kinase
cascade, or the p85 regulatory subunit of PI3-kinase, which stimulates
signaling pathways ultimately leading to pp70 S6-kinase (10, 11),
4EBP1/PHAS-1 (12), or Akt/PKB activation (13). PI3-kinase is strongly
implicated in both metabolic and mitogenic signaling (14), as is its
downstream effector Akt (15-17).
This paper reports experiments aimed at understanding the mechanism by
which adipocytes develop ligand selectivity such that insulin, but not
PDGF, stimulates anabolic metabolism. We assessed the ability of
insulin and PDGF to regulate numerous signaling molecules, particularly
PI3-kinase and Akt isoforms 1 and 2, due to their relevance to anabolic
metabolism (18-21). We were particularly interested in Akt2, primarily
because of two recent reports suggesting a role for this particular
isoform in GLUT4 translocation (22, 23). The relative effectiveness of
PDGF and insulin at activating different Akt isoforms in 3T3-L1
adipocytes has been unclear. Two laboratories (24, 25) reported that
insulin phosphorylates Akt on a key regulatory residue much more
strongly than does PDGF, whereas a third group reported that PDGF
stimulates Akt kinase activity at least 50-60% as well as insulin
(26). None of these studies distinguished between the relative
sensitivity of different Akt isoforms.
In the work presented below, we demonstrate that both Akt
isoforms are selectively responsive to insulin, and not PDGF, in 3T3-L1 adipocytes. PDGF still activated numerous other signaling molecules, including PI3-kinase, pp70 S6-kinase, 4EBP1/PHAS-1, and
mitogen-activated protein kinase, effectively in this tissue. PDGF was
also a potent stimulator of both forms of Akt in the precursor 3T3-L1
fibroblasts, suggesting that 3T3-L1 differentiation specifically
suppresses this signaling pathway. These experiments suggest a
mechanism by which redundant signaling pathways functional in precursor
cells can be altered to serve specific regulatory functions in
differentiated tissues.
 |
MATERIALS AND METHODS |
Antibodies and Reagents--
Polyclonal sheep anti-GLUT4
antibodies were raised against a glutathione S-transferase
fusion protein encoding the last 31 amino acids of the GLUT4 carboxyl
terminus (glutathione
S-transferase-ISATFRRTPSLLEQEVKPSTELEYLGPDEND). Polyclonal
rabbit anti-Akt antibodies were raised against the carboxyl-terminal
sequences CHFPQFSYSASGTA in Akt1 and CDQTHFPQFSYSASIRE in Akt2.
Polyclonal rabbit anti-phospho-S6 antibodies were raised against the
major phosphorylation site in the ribosomal S6 subunit (CRRLpSpSPLRApSTSKpSEEpSQK; where pS represents phosphoserine). Anti-phospho-mitogen-activated protein kinase, phospho-Akt, and phospho-GSK antibodies were purchased from Promega (Madison, WI), New
England Biolabs (Beverly, MA), and Quality Controlled Biochemicals (Hopkintown, MA), respectively. Phospho-Akt antibodies were directed against the Ser473 or Thr308 phosphorylation
sites, while those against phospho-GSK recognize the Ser9
phosphorylation site. Monoclonal mouse anti-GSK-3
antibodies were
purchased from Transduction Laboratories (Lexington, KY). Agarose-bound
anti-phosphotyrosine antibodies were from Upstate Biotechnology, Inc.
(Lake Placid, NY). Anti-hemagglutinin antibodies were obtained from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-pp70 S6-kinase
antibodies and glutathione S-transferase S6 peptide
substrate were generously donated by Margaret Chou (University of
Pennsylvania). Anti-PHAS-1 antibodies were kindly provided by John
Lawrence (University of Virginia). Wortmannin was purchased from Sigma,
and porcine insulin was a gift from Lilly. PDGF-BB was purchased from
Life Technologies, Inc.
Akt Constructs, Retroviral Infection, and Cell
Culture--
3T3-L1 fibroblasts were differentiated into adipocytes 2 days postconfluence in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 1 µg/ml dexamethasone, and
112 µg/ml isobutylmethylxanthine. After 3 days, cells were maintained in DMEM supplemented with 10% fetal bovine serum. Prior to
analysis, 3T3-L1 adipocytes were serum-starved as described in the
figure legends. Cells were subsequently stimulated with either 100 nM insulin or 50 ng/ml PDGF.
The mouse Akt1 and human Akt2 constructs were generously provided by
Phillip Tsichlis and Joseph Testa, respectively, of the Fox Chase
Cancer Center (Philadelphia, PA). The HA-tagged Akt2 construct was
generated by PCR using the cDNA encoding Akt2 as a template and the
primers 5'-GCC ATC CGA AAG CTT GCT GCC ACC ATG TAC CCT TAT GAT GTG CCA
GAT TAT GCC AAT GAG GTG TCT GTC ATC-3' (forward) to generate a
hemagglutinin epitope tag at the N terminus of the protein and
HindIII restriction site and 5'-ACA TAA TGC AGA TCT TCA CTC
GCG GAT GCT GGC CGA GTA-3' (reverse) to create a BglII site.
Akt1, Akt2, and the newly generated HA-Akt2 were then cloned into the
murine retroviral vector pLNCX1, which bears a neomycin resistance gene
to allow for selection of infected cells. All constructs were
sequenced, and no errors were found. The constructs were packaged into
replication-incompetent retrovirus following CaPO4
transfection into ecotropic Phoenix cells. Supernatants containing the
retrovirus encoding HA-Akt2 were used to infect 3T3-L1 fibroblasts
using the method of Hudson et al. (1992). Cells infected
with the retrovirus were selected with 800 µg/ml G418 (active
concentration), and colonies of G418-resistant cells were pooled.
Glucose Uptake and GLUT4 Translocation Assays--
Methods for
measuring glucose uptake rates and plasma membrane GLUT4 levels (using
the plasma membrane "sheet" assay) have been described (21).
Protein Immunoblotting, Immunoprecipitation, and
Activity--
Western blots of total cell lysates were prepared and
analyzed as described previously (27). Akt kinase assays were conducted as described previously (27) except that Akt kinase assays were conducted for only 15 min. Phospho-Akt and phospho-GSK antibodies were
used at concentrations recommended by the manufacturer.
Phosphotyrosine-containing proteins were immunoprecipitated by
solubilizing cells as described for Akt kinase assays and incubating
with 20 µl of agarose-conjugated anti-phosphotyrosine antibodies.
Following a 1-3-h incubation at 4 °C, agarose was washed three
times in ice-cold lysis buffer without protease inhibitors and
solubilized in Laemmli sample buffer. GSK was immunoprecipitated
identically with the exception that monoclonal anti-GSK antibodies were
coupled to agarose-conjugated anti-mouse antibody. PI3-kinase assays
were performed using methods previously described (28).
For pp70 S6-kinase assays, cells were harvested in lysis buffer (7 mM K2HPO4, 3 mM
KH2PO4, 1 mM EDTA, 5 mM
EGTA, 10 mM MgCl2, 50 mM
-glycerophosphate, 0.5% Nonidet P-40, 1 mM
phenylmethylsulfonyl fluoride, and inhibitors 1 mM sodium
orthovanadate, 1 mM dithiothreitol, 10 µg/ml leupeptin,
10 µg/ml pepstatin, pH 7.3), incubated on ice for 10 min, and
centrifuged at 23,000 × g for 10 min at 4 °C.
Cleared lysates (~1 mg of protein) were immunoprecipitated with
anti-pp70 antibody (1.5-2 h, 4 °C) followed by the addition of
activated staphylococcus (1 h, 4 °C). Immune complexes were washed
once with each of the following buffers: buffer A (10 mM Tris, pH 7.2, 100 mM NaCl, 1 mM EDTA, 1%
Nonidet P-40, 0.5% sodium deoxycholate with inhibitors, pH 7.2), high
salt buffer (10 mM Tris, 1 M NaCl, 0.1%
Nonidet P-40 with inhibitors, pH 7.2), and ST buffer (100 mM Tris, 150 mM NaCl with inhibitors, pH 7.2). Kinase reactions were performed by adding 30 µl of kinase mixture to
each immune complex (20 mM HEPES, pH 7.2, 10 mM
MgCl2, 1 mg/ml BSA, 50 µM ATP, 0.03 µg of
protein kinase inhibitor, 1-2 µg of glutathione
S-transferase S6 peptide substrate, and 10 µCi of [32P-
]ATP) and incubating each sample 10 min in a
30 °C water bath. Reactions were stopped by the addition of Laemmli
sample buffer. Samples were analyzed by SDS-PAGE (12% gel), and
32P incorporation was quantitated by PhosphorImager
analysis (Molecular Dynamics, Inc., Sunnyvale, CA).
mRNA Isolation, RT-PCR, and Restriction
Analysis--
mRNA was isolated from 3T3-L1 cells before and after
differentiation using the MicroPoly(A) PureTM mRNA isolation kit
from Ambion. Approximately 50 ng of mRNA was reverse transcribed
for 1 h at 48 °C by avian myeloblastosis virus reverse
transcriptase for first strand cDNA synthesis primed by the
antisense primer (5'-CTGGCTGAGTAGGAGAACTGGGG-3') after a brief
denaturation of the template and primer for 2 min at 94 °C.
Tfl DNA polymerase was used for second strand synthesis and
PCR, primed by the antisense primer and the sense primer
(5'-CCTGCCCTTCTACAACCAGGACC-3'). Amplification resulted from 40 cycles
of denaturation, annealing, and extension for 30 s at 94 °C, 1 min at 60 °C, and 1 min at 68 °C, respectively. The sense primer
corresponds to Akt1 nucleotides 1038-1060 or Akt2 nucleotides
1041-1063. Antisense primer corresponds to Akt1 nucleotides 1408-1430
or Akt2 nucleotides 1411-1433. RT-PCR reagents and protocols are
derived from the ACCESS RT-PCR System (Promega). Other RT-PCR systems
(Perkin-Elmer) produced the same results.
The RT-PCR products were purified by using the QIAquickTM PCR
purification kit (QIAGEN) and digested overnight with excess units of
BstEII (New England Biolabs) at 60 °C. The digested
RT-PCR products were resolved by 1.4% agarose, 1× TBE gel
electrophoresis and visualized by ethidium bromide staining. Control
for completion of digestion was confirmed by digesting PCR product
using cloned mouse Akt1 cDNA.
 |
RESULTS |
Several groups have found that PDGF is incapable of activating
glucose uptake in 3T3-L1 adipocytes (5, 7). Nonetheless, there are two
reports in which PDGF does stimulate glucose uptake in wild-type 3T3-L1
adipocytes (29) or rat adipocytes overexpressing PDGF receptors (30).
To determine whether PDGF is capable of activating glucose transport
and GLUT4 translocation in the 3T3-L1 adipocytes used in our
laboratory, we assayed these events after a 10-min treatment with
either insulin (100 nM) or PDGF (50 ng/ml). Insulin, but
not PDGF, stimulated both the uptake of
2-[3H]deoxyglucose (Fig.
1A) and the appearance of cell
surface GLUT4 (Fig. 1B). In light of the similarities among
the known signaling mechanisms for either agonist, one explanation for
this difference was that PDGF additionally activated "inhibitory
mechanisms" that prevented its enhancement of certain metabolic
events. While previous studies have demonstrated the existence of
inhibitory "cross-talk" between insulin and PDGF pathways when PDGF
is added prior to insulin (24, 31), simultaneous addition of the
peptides had not been investigated in detail. As shown in Fig. 1,
A and B, concomitant addition of insulin and PDGF
resulted in stimulation of glucose uptake and GLUT4 translocation
equivalent to insulin alone.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 1.
Effect of PDGF and/or insulin on metabolic
signaling in differentiated 3T3-L1 adipocytes. A, the
uptake of 2-[3H]deoxyglucose was measured following a
10-min stimulation with PDGF (50 ng/ml) and/or insulin (100 nM) of differentiated 3T3-L1 adipocytes grown in 12-well
dishes. The nonspecific background measured in cells exposed to
cytochalasin B in the absence of insulin was subtracted from all
values. The results shown are means ± S.E. of three independent
experiments performed in triplicate. B, adipocytes grown on
coverslips were treated as above before preparation of plasma membrane
sheets. The plasma membrane sheets were subjected to immunofluorescence
microscopy using polyclonal sheep anti-GLUT4 antibodies and
rhodamine-conjugated anti-sheep secondary antibodies. Images were
captured using a digital camera. Data are representative of four
independent experiments. C, 3T3-L1 fibroblasts or adipocytes
were serum-starved 20-24 h in DMEM containing 10 mM HEPES
and 0.5% BSA before stimulation with either 50 ng/ml PDGF or 1 µM insulin for 10 min. Total cell lysates (40 µg of
protein) were resolved by SDS-PAGE, transferred to nitrocellulose, and
probed with either anti-phosphotyrosine or
anti-phospho-mitogen-activated protein kinase antibodies. Data are
representative of two independent experiments. D, 3T3-L1
adipocytes were serum-starved for 2 h in Leibovitz's L-15 medium
containing 0.2% BSA and then stimulated with PDGF (50 ng/ml) and/or
insulin (100 nM) for 10 min. PI3-kinase was
immunoprecipitated using anti-phosphotyrosine antibody, and kinase
activity was assayed using phosphatidylinositol as substrate. Kinase
reactions were spotted onto thin layer chromatography plates and
visualized by autoradiography. Data are representative of two
independent experiments.
|
|
Despite PDGF's inability to activate these metabolic responses, PDGF
does signal other events as effectively as insulin in this cell type.
In both 3T3-L1 fibroblasts and adipocytes, insulin stimulated the
tyrosine phosphorylation of insulin and/or IGF-1 receptors, while PDGF
induced tyrosine phosphorylation of the PDGF receptor (Fig.
1C, upper panel). Moreover, in both cell types, insulin and PDGF stimulated phosphorylation of mitogen-activated protein kinase (Fig. 1C, lower panel). Since
PI3-kinase is critical for activation of anabolic metabolism, as well
as signaling molecules such as Akt and pp70 S6-kinase (10, 13, 18, 32),
its activity in anti-phosphotyrosine immunoprecipitates was measured.
Insulin and PDGF treatment, respectively, stimulated PI3-kinase
100-fold over basal level, and the precipitated activity roughly
doubled when both agonists were added simultaneously (Fig.
1D). These results are consistent with prior reports that
PDGF receptors mediate activation of PI3-kinase in 3T3-L1 adipocytes,
but this is not sufficient for activation of glucose transport (7).
As described above, prior studies have been contradictory regarding
whether Akt is activated by PDGF in 3T3-L1 adipocytes. Two reports have
shown that insulin is significantly more potent than PDGF in increasing
Akt phosphorylation by using phosphospecific antisera directed against
the regulatory Ser473 site on Akt1. In contrast, Tanti
et al. (26) found that PDGF is quite effective at
stimulating Akt activity as measured in the immune complex, achieving a
level of activation that is at least 50% that induced by insulin. In
addition to being contradictory, these prior studies have not
distinguished between activation of each isoform. To resolve these
apparent discrepancies, we used four different approaches to evaluate
the regulation of Akt isoforms 1 and 2 by insulin and PDGF in 3T3-L1
fibroblasts and adipocytes. First, we used
anti-phospho-Ser473 antisera, which, as shown below,
specifically recognizes phosphorylated Akt1, but not Akt2, and
anti-phospho-Thr308 antisera, which recognizes both Akt1
and Akt2 isoforms. Second, we produced an antibody specific for Akt2
that could detect both an agonist-induced mobility shift when the
proteins were separated on SDS-polyacrylamide gels and could
immunoprecipitate endogenous Akt2 kinase activity from intact cells.
Third, we expressed an epitope-tagged form of Akt2 in 3T3-L1 cells and
then measured the shift and kinase activity of this construct using
antibodies against the HA epitope. And fourth, we measured the degree
of phosphorylation of the Akt substrate GSK-3
in vivo,
which serves as a marker of endogenous Akt kinase activity in the
intact cell.
To characterize the isoform preference for the phosphospecific antibody
directed against the regulatory Ser473 phosphorylation
site, Akt1 and Akt2 isoforms were expressed in 3T3-L1 cells. Using an
antibody raised against the carboxyl terminus of Akt1 but that actually
recognizes both isoforms, we demonstrated that these proteins were
overexpressed severalfold and that Akt2 migrated slightly faster than
Akt1 when resolved on SDS-polyacrylamide gels (Fig.
2A). Electrophoresis
conditions were not optimized in this experiment to detect an
agonist-induced mobility shift, which is generally less pronounced
using this antibody as compared with the Akt2-specific antibody
described below. When the phospho-Ser473 antibody was used
to investigate Akt phosphorylation in these lysates, it detected
phosphorylated Akt in Akt1-expressing 3T3-L1 adipocytes that were
stimulated by insulin but not PDGF (Fig. 2B, upper
panel). However, as seen in longer exposures (Fig. 2B, lower panel), the antibody only detected endogenous Akt and
not the overexpressed construct in cells stably expressing Akt2.
Prolonged exposure of the blots also indicated that overexpressed Akt1
was recognized by the anti-phospho-Ser473 antibody to some
degree under basal conditions, but this was augmented only by insulin
and not PDGF. Faint reactivity with the phosphospecific Akt antibody
was sometimes observed in the PDGF-stimulated adipocyte lysates, but it
was always markedly less than that seen in response to insulin.
Collectively, these results indicate that the
anti-phospho-Ser473 antibody is specific for the Akt1
isoform and that insulin stimulates Akt1 phosphorylation much more
potently than does PDGF in 3T3-L1 adipocytes.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 2.
Insulin-specific Ser473
phosphorylation of Akt1 in 3T3-L1 adipocytes. A
(upper panel), 3T3-L1 adipocytes stably expressing an empty
vector, Akt1, or Akt2 were serum-starved for 20-24 h in DMEM
containing 10 mM HEPES and 0.5% BSA before treatment
without ( ) or with insulin (I, 1 µM) for 10 min. Total cell lysates were resolved by SDS-PAGE, transferred to
nitrocellulose, and detected with antibodies directed against the
carboxyl terminus of Akt1 (anti-Akt). In these experiments,
electrophoresis conditions were not optimized to resolve
insulin-stimulated mobility shifts, which are evident in later figures.
B, these same cell lines were treated as above, except some
cells received PDGF (P, 50 ng/ml). Total cell extracts were
again resolved by SDS-PAGE, transferred to nitrocellulose, and probed
with anti-phospho-Akt antibodies directed against the
Ser473 phosphorylation site (anti-PAkt (S473)).
Detection in all cases was by enhanced chemiluminescence, and
representative blots are shown following a short (30-s) or long (4-min)
exposure.
|
|
To investigate whether PDGF affected Akt1 in the adipocyte precursor
cells, 3T3-L1 fibroblasts, we again investigated PDGF's ability to
increase phosphorylation of Akt1 using the
phospho-Ser473-specific antibody. As demonstrated in Fig.
3, PDGF stimulated Ser473
phosphorylation comparably with insulin in 3T3-L1 fibroblasts. Insulin
was used at a concentration of 1 µM, and under these
conditions it is likely to be binding to IGF-1 receptors. Akt1 is also
phosphorylated on a second regulatory site, Thr308. Using a
phosphospecific antibody that recognizes this second regulatory site
(as well as the analogous Thr309 site in Akt2), we found
that this residue was phosphorylated in response to both insulin and
PDGF in 3T3-L1 fibroblasts but was selectively responsive to insulin in
differentiated 3T3-L1 adipocytes (Fig. 3). Phosphorylation of either
site was blocked by pretreatment with wortmannin, confirming their
PI3-kinase dependence in adipocytes. These studies suggest that
differentiation actually suppresses signaling events "downstream"
of PI3-kinase, and suggests a more complicated pattern of regulation of
Akt1.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of differentiation on Akt1
phosphorylation. 3T3-L1 fibroblasts (left panels) and
adipocytes (right panels) were serum-starved for 2 h in
Leibovitz-15 medium containing 0.2% BSA before treatment with PDGF (50 ng/ml; PDGF) or insulin (1 µM for fibroblasts,
100 nM for adipocytes; Insulin) for 10 min.
Adipocytes were pretreated with (+) or without ( ) 100 nM
wortmannin for 30 min prior to the addition of insulin. Total cell
extracts were prepared, resolved by SDS-PAGE, transferred to
nitrocellulose, and probed with anti-phospho-Ser473 or
anti-phospho-Thr308 antibodies.
|
|
Because of the isoform specificity of the phospho-Akt antibody, the
previously published studies could not address whether the more
relevant Akt2 isoform was differentially phosphorylated in 3T3-L1
adipocytes. An indication of the importance of investigating Akt2 is
its altered expression during the course of 3T3-L1 differentiation. This was demonstrated using a quantitative reverse transcription PCR
assay. An oligonucleotide primer pair identical in both isoforms was
used for RT-PCR amplification. The regions amplified between the two
primers in Akt1 and Akt2 were identical in size and highly similar in
sequence; thus, the PCR amplification of both isoforms should occur
with virtually the same efficiency in a single reaction mixture. After
the RT-PCR, the product was subjected to a restriction digest at a site
present in Akt1, but not Akt2, and the products were resolved by gel
electrophoresis to determine which isoform amplification was greater
relative to the other. Comparison between 3T3-L1 fibroblasts and 3T3-L1
adipocytes showed a marked increase in the level of the undigested
versus digested fragment of the PCR product, indicating an
increase in the ratio of Akt2 mRNA relative to Akt1 mRNA upon
differentiation (Fig. 4). Altomare et al. (33) report a similar relationship between Akt1 or
Akt2 mRNA levels during the course of 3T3-L1 differentiation using Northern analysis.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 4.
Akt2 is up-regulated upon adipogenesis
relative to Akt1 as determined by quantitative RT-PCR.
A, schematic representation of the RT-PCR strategy. The
primers depicted correspond to sequences that are identical between
Akt1 and Akt2 and amplify a 392-bp region. Reverse transcription of
isolated mRNA with the antisense primer and subsequent PCR with
sense and antisense primers results in amplification of both Akt1 and
Akt2 in the same reaction. However, the amplified 392-bp region of Akt1
has a BstEII site unique to it and absent in the
corresponding region of Akt2. BstEII digestion of the Akt1
fragment produces two fragments (243 and 149 bp), while Akt2 is
resistant to BstEII digestion. The intensity of the 392-bp
fragment reflects the amount of Akt2, and while the intensity of the
243- and 149-bp fragment reflects the amount of Akt1. B,
ethidium bromide-stained agarose gel eletrophoresis showing that Akt2
relative to Akt1 is up-regulated in 3T3-L1 cells after differentiation
into adipocytes; 3T3-L1 fibroblasts were differentiated into adipocytes
in culture. mRNA was isolated before and after differentiation and
used for the RT-PCR/restriction digest assay described in A.
Upon differentiation, the intensity of the 392-bp band (Akt2) increases
relative to the 243- and 149-bp bands (Akt1). The white
asterisks highlight the 500-bp band of a 100-bp ladder (New
England Biolabs).
|
|
Due to the likely relevance of Akt2 to metabolic signaling, we
conducted an exhaustive series of experiments to detect whether Akt2
was also differentially stimulated by insulin, and not PDGF, in 3T3-L1
adipocytes. An Akt2-specific antibody raised against a
carboxyl-terminal regulatory domain was produced. This antibody preferentially recognized the overexpressed Akt2, but not Akt1 (Fig.
5A). The Akt2-specific
antibody also detected a dramatic electrophoretic mobility shift in
parental 3T3-L1 cells in response to stimulation and detected increased
Akt2 expression during the course of differentiation (Fig.
5B). Insulin, but not PDGF, elicited this mobility shift in
3T3-L1 adipocytes (Fig. 5C). The PI3-kinase inhibitor
wortmannin completely inhibited the mobility shift in adipocytes (Fig.
5C), confirming that insulin promoted phosphorylation of
Akt2 through a PI3-kinase-dependent mechanism in this cell type. PDGF was capable of eliciting this mobility shift in 3T3-L1 fibroblasts (Fig. 5C).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 5.
Insulin-specific stimulation of an Akt2
electrophoretic mobility shift. A, the lysates used in
Fig. 2A were resolved by SDS-PAGE, transferred to
nitrocellulose, and incubated with antibodies directed against the
carboxyl terminus of Akt2. B, the effect of adipocyte
differentiation on Akt2 expression was evaluated. 3T3-L1 fibroblasts
underwent the differentiation protocol described, and lysates were
prepared starting at day 0 (just before the addition of differentiation
medium) and ending on day 9. Prior to lysis, cells were serum-starved
as described in Fig. 1 and then stimulated without ( ) or with 1 µM insulin (I) for 10 min. Following
resolution on SDS-PAGE and transfer to nitrocellulose, proteins were
detected with anti-Akt2 antibodies and enhanced chemiluminescence.
C, 3T3-L1 fibroblasts (left panel) and adipocytes
(right panel) were treated without or with (+W)
wortmannin (250 nM) 30 min prior to stimulation with PDGF
(PDGF, 50 ng/ml) or insulin (Ins, 1 µM for fibroblasts, 100 nM for adipocytes)
for 10 min.
|
|
As described above, a prior study reported that PDGF significantly
stimulated endogenous Akt kinase activity when measured in an immune
complex assay (26). Using the isoform-specific Akt2 antibodies, we
similarly observed a significant PDGF stimulation of Akt2 kinase
activity in immune complex assays (Fig.
6). Because activation of Akt kinase did
not correlate with phosphorylation on the major regulatory sites,
Ser473 and Thr308, there was concern that some
of the activity measured in the immune complex might be due to another
hormone-sensitive kinase contaminating the immune complex assay. To
evaluate this, HA-tagged Akt2 was expressed in 3T3-L1 adipocytes at
levels 2-5 times higher than endogenous Akt2. If Akt2 were associating
with a limiting kinase also activated by insulin, overexpression should
allow a more definitive assay. Moreover, use of the anti-HA antibody also excludes potential cross-reactivity of the Akt2 antibody with
another protein kinase. Western blot analysis of the electrophoretic mobility shift of the overexpressed HA-Akt2 construct revealed that
both insulin and PDGF retarded its electrophoretic mobility in
fibroblasts (Fig. 7A), but
only insulin elicited the shift in adipocytes (Fig. 7C).
This change in mobility could be detected with both anti-HA and
anti-Akt2 antibodies. Kinase activity of the overexpressed Akt2 was
ascertained in immunoprecipitates using anti-HA antisera. In
fibroblasts, PDGF was significantly more effective than insulin at
stimulating HA-Akt2 kinase activity (Fig. 7B). Following
differentiation, however, insulin's stimulation of HA-Akt2 was roughly
10-fold greater than that of PDGF (Fig. 7D). Similar results
were obtained using the anti-Akt2 antibodies in the overexpressing cell
lines, although the antibody precipitated less total activity (data not
shown).

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 6.
Effect of differentiation on Akt2 kinase
activity. 3T3-L1 fibroblasts (left panels) and
adipocytes (right panels) were serum-starved for 20-24 h in
DMEM containing 10 mM HEPES and 0.5% BSA before treatment
with PDGF (50 ng/ml; PDGF) or insulin (1 µM,
Ins) for 10 min. Akt2 in vitro immune complex
kinase reactions were performed as described, and
32P-incorporation into histone 2B was visualized by
autoradiography or quantitated by PhosphorImager analysis (Molecular
Dynamics). Results shown are the means ± S.E. of three
independent experiments.
|
|

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 7.
Electrophoretic mobility and kinase activity
of HA-Akt2 in 3T3-L1 fibroblasts and adipocytes. 3T3-L1
fibroblasts (A and B) or adipocytes (C
and D) overexpressing HA-Akt2 were serum-starved for 2 h in Leibovitz's L-15 medium containing 0.2% BSA before treatment
with PDGF (50 ng/ml; P) or insulin (1 µM for
fibroblasts, 100 µM for adipocytes; I) for 10 min. A and C, total cell extracts were resolved
by SDS-PAGE, transferred to nitrocellulose, and probed with anti-HA or
anti-Akt2 antibodies. B and D, Akt in
vitro immune complex kinase reactions were performed as described
using anti-HA antibodies for immunoprecipitation. 32P
incorporation into histone 2B was visualized by autoradiography and
quantitated by PhosphorImager analysis (Molecular Dynamics). Results
shown are the means ± S.E. of three independent
experiments.
|
|
As a final means for ascertaining Akt kinase activity, we evaluated the
degree of phosphorylation of an endogenous substrate for Akt, GSK-3
.
A prior study (25) measured the effects of insulin and PDGF on GSK-3
kinase activity and found that PDGF inhibited GSK-3
kinase activity
about half as well as insulin. However, several molecules have been
reported to affect GSK-3
kinase activity (34), while only Akt is
known to phosphorylate GSK-3
on the regulatory serine 9 residue.
Moreover, GSK-3
kinase activity is inhibited only ~50% in
response to insulin or other agonists (25, 35), while changes in
GSK-3
phosphorylation are much easier to detect. Thus, we chose to
measure GSK-3
phosphorylation on the Akt target residue, serine 9, as an indication of endogenous Akt kinase activity. GSK-3
was
immunoprecipitated from insulin- and PDGF-stimulated cells using
monoclonal anti-GSK-3
antibodies and subjected to Western blotting
with an antibody directed against the phosphorylated serine 9 site of
GSK3
. In fibroblasts, both insulin and PDGF stimulated GSK-3
phosphorylation; in adipocytes, however, PDGF-induced GSK-3
phosphorylation was much less pronounced (Fig.
8). Thus, in vivo
phosphorylation of an endogenous substrate of Akt precisely reflects
the insulin/PDGF specificity suggested by phosphorylation of Akt or the
in vitro activity of overexpressed Akt. This is perhaps the
best measure of Akt kinase activity, since this is not subject to
potential artifacts associated with measuring immunoprecipitated kinase
activity but rather is likely to reflect the total amount of Akt kinase
activity present in the intact cell.

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 8.
Akt kinase activity in 3T3-L1 fibroblasts and
adipocytes measured by phosphorylation of GSK-3 , an in
vivo substrate. 3T3-L1 fibroblasts (left)
and adipocytes (right) were serum-starved for 2 h in
Leibovitz's L-15 media containing 0.2% BSA before treatment with PDGF
(50 ng/ml; P), insulin (1 µM; I),
or no stimulation ( ). GSK-3 was immunoprecipitated using
anti-GSK-3 antibodies and resolved by SDS-PAGE. GSK-3
phosphorylation was detected by probing Western blots with
anti-phospho-GSK-3 antibodies. Data are representative of two
independent experiments.
|
|
The ability of PDGF to activate PI3-kinase as measured in the immune
complex, but not stimulate Akt, raised the question of whether
signaling-competent 3'-phosphoinositides were being generated in
response to PDGF in the intact cell. Thus, we chose to look at two
downstream targets that require polyphosphoinositide production for
activation. PDGF reportedly stimulates pp70 S6-kinase activity, and a
mobility shift in 3T3-L1 adipocytes (24) and, in other cell types,
PI3-kinase is required for pp70 S6-kinase activation (11). In both the
3T3-L1 fibroblasts and adipocytes used in this study, both PDGF and
insulin stimulated phosphorylation of pp70 S6-kinase as demonstrated by
an upward electrophoretic mobility shift on Western blots (Fig.
9A). Two other assays revealed
that adipocyte pp70 S6-kinase was activated comparably by both insulin and PDGF in 3T3-L1 adipocytes: 1) both insulin and PDGF activated pp70
S6-kinase roughly 3-4-fold as measured by immune complex kinase assays
using ribosomal S6 peptide as substrate (Fig. 9B); and 2)
PDGF and insulin both induced the phosphorylation in vivo of
pp70 S6-kinase's endogenous substrate, ribosomal protein S6 (Fig.
9B). Phosphorylation of S6 was detected by probing total cell lysates with anti-phospho-S6 antibodies following stimulation of
adipocytes with either PDGF or insulin. Submaximal insulin doses had
similar effects on the insulin-stimulated shift of both Akt and pp70
S6-kinase, further suggesting that the two enzymes respond similarly to
insulin stimulation (Fig. 9C). Finally, stimulation of pp70
S6-kinase by either insulin or PDGF was blocked by pretreatment with
the PI3-kinase inhibitor wortmannin (Fig. 9D) or LY294002 (Fig. 9E), confirming PI3-kinase dependence for pp70
S6-kinase activation. These data provide confirmation that functional
3'-phosphoinositides are generated in response to PDGF, since their
production is required for stimulation of pp70 S6-kinase.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 9.
Activity of pp70 S6 kinase following
stimulation of 3T3-L1 adipocytes with PDGF or insulin. In
A-C, 3T3-L1 fibroblasts or adipocytes were serum-starved
for 2 h in KRP buffer containing 0.2% BSA. In D and
E, cells were additionally stepped down in DMEM containing
10 mM HEPES and 0.5% BSA prior to the incubation in KRP.
In A-E, cells were stimulated with either PDGF (50 ng/ml;
P), insulin (100 nM; I), or no
stimulation ( ), while in C cells were stimulated with the
indicated concentration of insulin, for 10 min prior to lysis.
A, following stimulation, total cell lysates (50 µg of
protein) from 3T3-L1 fibroblasts or adipocytes were resolved by
SDS-PAGE, transferred to nitrocellulose, and probed with anti-pp70 S6
kinase antibodies to detect an agonist-induced mobility shift.
B, upper panel, following stimulation, pp70
S6-kinase was immunoprecipitated from 3T3-L1 adipocytes using
polyclonal anti-pp70 antibodies, and in vitro kinase
reactions were performed on the immune complexes. Reactions proceeded
for 10 min at 30 °C and were resolved by SDS-PAGE. 32P
incorporation into glutathione S-transferase S6 peptide was
visualized by autoradiography and quantitated by PhosphorImager
analysis (Molecular Dynamics). B, lower panel,
total cell lysates (50 µg of protein) from stimulated 3T3-L1
adipocytes were resolved by SDS-PAGE, transferred to nitrocellulose,
and probed with anti-phospho-S6 antibodies. C, total cell
lysates from 3T3-L1 adipocytes (50 µg of protein) treated with the
indicated concentrations of insulin were resolved by SDS-PAGE,
transferred to nitrocellulose, and probed with anti-pp70 S6 kinase or
anti-Akt2 antibodies. D, the PI3-kinase inhibitor LY294002
(100 µM) was added to 3T3-L1 adipocytes 30 min prior to
stimulation with insulin or PDGF. Total cell lysates were resolved by
electrophoresis and detected with antibodies against pp70 S6 kinase or
the phosphorylated species of ribosomal S6 protein as described above.
E, the PI3-kinase inhibitor wortmannin (250 nM)
was added to 3T3-L1 adipocytes for the last 30 min prior to stimulation
with insulin or PDGF. Total cell lysates were resolved by
electrophoresis and detected with antibodies against pp70 S6 kinase or
the phosphorylated species of ribosomal protein S6. Identical results
were obtained using 100 nM wortmannin.
|
|
A second signaling molecule downstream of PI3-kinase is the
translational repressor PHAS-1 (also called 4EBP1). PHAS-1 is phosphorylated on multiple different sites by the protein mTOR (mammalian target of rapamycin), but the molecular events activating mTOR are a subject of debate. We evaluated the relative actions of
insulin and PDGF on PHAS-1 phosphorylation, which can be detected by a
reduction in electrophoretic mobility when the protein is resolved on
SDS-PAGE gels (36). Like pp70 S6-kinase, PHAS-1 was phosphorylated in
response to both insulin and PDGF (Fig. 10), although the former was more
effective. The shift in mobility could be inhibited by wortmannin (Fig.
10) or LY294002 (data not shown). These data indicate that PDGF is
capable of generating PI3-kinase-dependent signals leading
to phosphorylation of pp70 S6-kinase and PHAS-1 in 3T3-L1
adipocytes.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 10.
Phosphorylation of PHAS-1 response to
insulin and PDGF in 3T3-L1 adipocytes. 3T3-L1 adipocytes were
serum-starved 18-24 h in DMEM with 0.5% BSA and 10 mM
Hepes and then starved for an additional 2 h in KRP containing
0.2% BSA before treatment with nothing (B), PDGF (50 ng/ml;
P), or insulin (100 nM; I) for 10 min. Certain samples were pretreated with 250 nM wortmannin
30 min prior to insulin. Total protein (40 µg) was resolved by
SDS-PAGE, transferred to nitrocellulose, and probed with anti-PHAS-1
antibody. Identical results were obtained using 100 nM
wortmannin.
|
|
 |
DISCUSSION |
The data presented in this report demonstrate that Akt isoforms 1 and 2 are activated significantly by insulin, but not PDGF, in
differentiated 3T3-L1 adipocytes. Evidence supporting this conclusion
includes the following: 1) insulin, but not PDGF, stimulated Akt1
phosphorylation in 3T3-L1 adipocytes, as detected using phosphospecific antibodies recognizing a regulatory Ser473 site on Akt1; 2)
insulin, but not PDGF, decreased the electrophoretic mobility of Akt2
separated on polyacrylamide gels; 3) insulin, but not PDGF, stimulated
phosphorylation of Akt1 and/or Akt2 on the regulatory
Thr308 or Thr309 site, respectively; 4) insulin
was a much more potent activator of HA-Akt2 kinase than PDGF as
measured in the immune complex; and 5) insulin, but not PDGF,
stimulated phosphorylation of the endogenous Akt substrate GSK-3
.
This last assay is most convincing, since it demonstrates insulin
selectivity of Akt activation in the intact cell. Other signaling
molecules are activated comparably in this differentiated tissue,
including the upstream lipid kinase PI3-kinase and its downstream
targets pp70 S6-kinase and PHAS-1. Insulin's ability to activate Akt
is adipocyte-specific, since PDGF was a potent stimulator of Akt
phosphorylation, electrophoretic mobility retardation, and kinase
activity, as well as GSK-3
phosphorylation, in preadipocyte 3T3-L1 fibroblasts.
The first experiments describing hormonal activation of Akt involved
expressed mutant PDGF receptors (13), and in these initial studies it
was determined that PI3-kinase is critical for PDGF-triggered Akt
activation. Subsequent studies indicated that expression of
constitutively active forms of PI3-kinase is sufficient to activate
endogenous Akt (37). Several different Akt isoforms have now been
identified (38, 39), all sharing a great deal of homology. These
isoforms are expressed fairly ubiquitously, and they have been
implicated in numerous cellular processes. Myriad studies have
implicated Akt in metabolic responses to insulin. Overexpression of
constitutively active forms of Akt stimulates glucose uptake and GLUT4
translocation (21, 26), as well as protein and lipid synthesis (21).
Expression of dominant-negative forms of Akt confirms a role for the
enzyme in insulin-stimulated glycogen (40) and protein (41) synthesis.
In other tissues Akt apparently participates more generally in
anti-apoptosis (42) and regulation of cell cycle (43).
The hypothesis that Akt plays a pivotal role in GLUT4 translocation has
been recently challenged (41), but this topic remains controversial
(44). Recently, the Akt2 isoform was found to specifically associate
with GLUT4-containing vesicles and to phosphorylate GLUT4 vesicle
resident proteins (22, 23). Furthermore, the sphingomyelin derivative
ceramide inhibits glucose uptake and GLUT4 translocation, and this
correlates with its ability to inhibit Akt phosphorylation and
activation (45). Thus, although the evidence that Akt is involved in
glucose uptake or GLUT4 translocation is controversial, this issue has
not been resolved. Regardless, Akt's contribution to
insulin-stimulated protein synthesis (41) and glycogen synthesis (40)
are strongly supported by the literature, confirming at least some role
for the enzyme in glucose metabolism. The data presented above indicate
that Akt2 expression increases markedly during the course of 3T3-L1
differentiation (Figs. 4 and 5), further implicating a role for this
isoform in insulin-stimulated metabolism.
Akt is also implicated in activation of two other signaling molecules,
pp70 S6-kinase and PHAS-1/4EBP1. Overexpression of constitutively
active forms of Akt stimulates phosphorylation of both molecules (13,
20), while expression of a dominant negative form blocks insulin's
stimulation of pp70 S6-kinase (41). Despite these studies, a mechanism
has been proposed whereby pp70 S6-kinase can be stimulated directly by
the upstream kinase PDK1 and thus not require Akt for activation (46).
In this paper, we present conditions where there is a lack of
correlation between the activation of pp70 S6-kinase, PHAS-1/4EBP1, and
Akt. Specifically, PDGF stimulates pp70 S6-kinase and PHAS-1 without
significantly affecting Akt, suggesting that Akt is dispensable for
pp70 S6-kinase or PHAS-1 activation under these conditions.
One hypothesis previously offered to explain PDGF's disproportionate
effects on activation of glucose uptake and PI3-kinase is that PDGF
does not target PI3-kinase to the appropriate subcellular compartment.
Several laboratories report that PDGF-stimulated PI3-kinase is located
primarily at the plasma membrane, while insulin-stimulated PI3-kinase
is predominantly microsomal (2, 3). Targeting sequences found in the
cytosolic IRS-1, but not the membrane-bound PDGF receptor, could
account for differences in localization. Moreover, some reports
indicate that insulin, but not PDGF, specifically targets PI3-kinase to
GLUT4 vesicles (9). This has been recently challenged, however, since
PI3-kinase was instead reported to associate with the cytoskeleton and
not the GLUT4 vesicle itself (47). While this model appears attractive with regard to GLUT4 vesicles, it is inherently more difficult to
explain how PDGF is capable of activating some cytosolic enzymes, such
as pp70 S6-kinase, but not others, such as Akt, using such a
compartmentalization model. Nonetheless, it remains a formal possiblity
that PDGF receptors and PI3-kinase could specifically be sequestered
from Akt in 3T3-L1 adipocytes. Overexpression of PDGF receptors
reportedly stimulates glucose uptake (30), perhaps because the elevated
expression of receptors saturates such sequestration events.
Intriguingly, expression of PDGF receptors incapable of activating
PI3-kinase still stimulates wortmannin-sensitive glucose transport
(30). These mutant receptors might be liberating endogenous PDGF
receptors from such sequestration mechanisms. We are currently investigating whether PDGF receptor overexpression releases the suppression of PDGF's activation of Akt.
An alternative possibility is that the activity of PI3-kinase as
measured in the immune complex assay may not reflect the levels of
phosphoinositides accumulated in vivo, possibly due to
differences in accessibility to substrate. A prior study reports that
although insulin and PDGF activate mitogen-activated protein kinase
comparably, only insulin stimulates the intracellular production of the
lipid product PIP3 (4). PIP3 could be critical
for activation of Akt, but not pp70. An alternative mechanism for
differential production of PIP3 is that PDGF, but not
insulin, stimulates a localized PIP3 phosphatase.
A third possibility is that insulin stimulates other signaling event
pathways in addition to those previously described that are required
for complete activation of Akt. If this is the case, such mechanisms
must themselves be specifically uncoupled from PDGF receptors during
the course of differentiation. In another recent report (48),
membrane-permeable analogs of PIP3 were found to be
incapable of stimulating glucose transport. However, when these
PIP3 analogs were added to wortmannin-treated cells stimulated with insulin, they were capable of stimulating transport. This experiment suggests that additional pathways are required for
activation of glucose transport, and future experiments will investigate whether this is also the case for Akt.
In addition to suggesting a role for Akt in insulin-stimulated glucose
metabolism, the data presented herein can be elaborated into a broader
hypothesis regarding the generation of a differentiated phenotype. The
development of specialized cells is accompanied by the acquisition of
novel morphological and biochemical characteristics. In white adipose
tissue, for example, features conferred by differentiation include a
reduced central cytoskeleton, the accumulation of a large and
metabolically active triglyceride droplet, and marked insulin-stimulatable glucose transport. The latter apparently depends
on the induction of the GLUT4 glucose transporter, although its
expression is clearly not sufficient (49). In complex, multisystem organisms, highly specialized functions are characterized by
exquisitely controlled regulation, often by extracellular ligands in
the form of hormones and growth factors. Thus, the mature cell must not only possess unique terminal outputs but must also display distinctive selectivity to unique arrays of extracellular signals. Based on the
current data, we propose that some cells confer this specificity via
selective suppression of signaling pathways present in a multipotent immature precursor cell (Fig. 11). This
process stands in contrast to the development of a new response, for
example the induction of a novel transporter isoform. However, the
elimination of an unwanted pathway appears a parsimonious strategy for
such a process as signal transduction, in which differentiated cells
utilize a common set of biochemical devices assembled into distinct
schemes. Nonetheless, at this point the establishment of such a
strategy as broadly utilized requires further experimentation.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 11.
Model for differentiation of 3T3-L1
adipocytes. In fibroblasts, both insulin/IGF-1 and PDGF receptors
couple to a diverse array of signaling pathways. Thus, either growth
factor effectively activates Akt, as well as pp70 S6 kinase and
mitogen-activated protein kinase. However, the fibroblast is incapable
of generating an authentic metabolic response, e.g. a marked
increase in glucose transport. Conversion to adipocytes is accompanied
by the acquisition of metabolic outputs, conferred by the induction of
GLUT4 as well as other proteins required both for augmentation of
hexose flux as well as other metabolic responses. In addition, the
mature adipocyte acquires specificity in terms of ligand responsiveness
by selectively suppressing the ability of non-insulin growth factors,
e.g. PDGF, to stimulate phosphorylation of Akt. Thus, the
mature phenotype well recognized in skeletal muscle and adipose tissue
displays not only a unique responsiveness in terms of the magnitude of
stimulation of glucose transport by insulin, but exquisite selectivity
in regard to the hormone or growth factor that elicits such a
response.
|
|
 |
ACKNOWLEDGEMENTS |
We are grateful to several individuals and
organizations for contributions to this work. Margaret Chou (University
of Pennsylvania) kindly donated anti-pp70 antibodies and provided
invaluable technical assistance with pp70 S6-kinase assays. John
Lawrence (University of Virginia) graciously donated anti-PHAS-1
antibodies. Joseph Testa (Fox Chase Cancer Center) generously provided
human Akt (
-isoform) cDNA. Cass Lutz (University of
Pennsylvania) provided assistance in the typing and editing of this manuscript.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants DK39615 (to M. J. B.) and DK09375 (to S. A. S.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
These authors contributed equally to this work.
¶
Supported by a Howard Hughes Pre-Doctoral Fellowship for the
Biological Sciences.
**
Supported by National Research Service Award for Training in Cell
and Molecular Biology GM07229.

To whom correspondence should be addressed: Howard Hughes
Medical Institute, University of Pennsylvania Medical School, 415 Curie
Blvd., Philadelphia, PA 19104. Tel.: 215-898-5001; Fax: 215-573-9138;
E-mail: birnbaum@hhmi.upenn.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
GLUT, glucose
transporter;
GSK, glycogen synthase kinase;
PI3-kinase, phosphatidylinositol 3-kinase;
BSA, bovine serum albumin;
HA, hemagglutinin;
PDGF, platelet-derived growth factor;
DMEM, Dulbecco's
modified Eagle's medium;
PCR, polymerase chain reaction;
RT-PCR, reverse transcription-PCR;
PAGE, polyacrylamide gel electrophoresis;
bp, base pair(s).
 |
REFERENCES |
| 1.
|
Birnbaum, M. J.
(1992)
Int. Rev. Cytol.
137A,
239-297[Medline]
[Order article via Infotrieve]
|
| 2.
|
Ricort, J. M.,
Tanti, J. F.,
Van Obberghen, E.,
and Le Marchand-Brustel, Y.
(1996)
Eur. J. Biochem.
239,
17-22[Medline]
[Order article via Infotrieve]
|
| 3.
|
Nave, B. T.,
Haigh, R. J.,
Hayward, A. C.,
Siddle, K.,
and Shepherd, P. R.
(1996)
Biochem. J.
318,
55-60
|
| 4.
|
Conricode, K. M.
(1995)
Biochem. Mol. Biol. Int.
36,
835-843[Medline]
[Order article via Infotrieve]
|
| 5.
|
Huppertz, C.,
Schwartz, C.,
Becker, W.,
Horn, F.,
Heinrich, P. C.,
and Joost, H.-G.
(1996)
Diabetologia
39,
1432-1439[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Isakoff, S. J.,
Taha, C.,
Rose, E.,
Marcusohn, J.,
Klip, A.,
and Skolnik, E. Y.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
10247-10251[Abstract/Free Full Text]
|
| 7.
|
Wiese, R. J.,
Mastick, C. C.,
Lazar, D. F.,
and Saltiel, A. R.
(1995)
J. Biol. Chem.
270,
3442-3446[Abstract/Free Full Text]
|
| 8.
|
Gould, G. S.,
Merrall, N. W.,
Martin, S.,
Jess, T. J.,
Campbell, I. W.,
Calderhead, D. M.,
Gibbs, E. M.,
Holman, G. D.,
and Plevin, R. J.
(1994)
Cell. Signalling
6,
313-320[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Heller-Harrison, R. A.,
Morin, M.,
Guilherme, A.,
and Czech, M. P.
(1996)
J. Biol. Chem.
271,
10200-10204[Abstract/Free Full Text]
|
| 10.
|
Cheatham, B.,
Vlahos, C. J.,
Cheatham, L.,
Wang, L.,
Blenis, J.,
and Kahn, C. R.
(1994)
Mol. Cell. Biol.
14,
4902-4911[Abstract/Free Full Text]
|
| 11.
|
Chung, J.,
Grammer, T. C.,
Lemon, K. P.,
Kazlauskas, A.,
and Blenis, J.
(1994)
Nature
370,
71-75[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Scott, P. H.,
Brunn, G. J.,
Kohn, A. D.,
Roth, R. A.,
and Lawrence, J. C. J.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
7772-7777[Abstract/Free Full Text]
|
| 13.
|
Burgering, M.,
and Coffer, P.
(1995)
Nature
376,
599-602[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Kapeller, R.,
and Cantley, L.
(1994)
BioEssays
16,
565-576[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Marte, B. M.,
and Downward, J.
(1997)
Trends Biochem. Sci.
22,
355-358[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Franke, T. F.,
Kaplan, D. R.,
and Cantley, L. C.
(1997)
Cell
88,
435-437[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Hemmings, B. A.
(1997)
Science
275,
628-630[Free Full Text]
|
| 18.
|
Okada, T.,
Kawano, Y.,
Sabakibara, T.,
Hazeki, O.,
and Ui, M.
(1994)
J. Biol. Chem.
269,
3568-3573[Abstract/Free Full Text]
|
| 19.
|
Kanai, F.,
Ito, K.,
Todaka, M.,
Hayashi, H.,
Kamohara, S.,
Ishii, K.,
Okada, T.,
Hazeki, O.,
Ui, M.,
and Ebina, Y.
(1993)
Biochem. Biophys. Res. Commun.
195,
762-768[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Kohn, A. D.,
Barthel, A.,
Kovacina, K. S.,
Boge, A.,
Wallach, B.,
Summers, S. A.,
Birnbaum, M. J.,
Scott, P. H.,
Lawrence, J. C., Jr.,
and Roth, R. A.
(1998)
J. Biol. Chem.
273,
11937-11943[Abstract/Free Full Text]
|
| 21.
|
Kohn, A. D.,
Summers, S. A.,
Birnbaum, M. J.,
and Roth, R. A.
(1996)
J. Biol. Chem.
271,
31372-31378[Abstract/Free Full Text]
|
| 22.
|
Kupriyanova, T. A.,
and Kandror, K. V.
(1999)
J. Biol. Chem.
274,
1458-1464[Abstract/Free Full Text]
|
| 23.
|
Calera, M. R.,
Martinez, C.,
Liu, H.,
El Jack, A. K.,
Birnbaum, M. J.,
and Pilch, P. F.
(1998)
J. Biol. Chem.
273,
7201-7204[Abstract/Free Full Text]
|
| 24.
|
Staubs, P. A.,
Nelson, J. G.,
Reichart, D. R.,
and Olefsky, J. M.
(1998)
J. Biol. Chem.
273,
25139-25147[Abstract/Free Full Text]
|
| 25.
|
Brady, M. J.,
Bourbonais, F. J.,
and Saltiel, A. R.
(1998)
J. Biol. Chem.
273,
14063-14068[Abstract/Free Full Text]
|
| 26.
|
Tanti, J. F.,
Grillo, S.,
Gremeaux, T.,
Coffer, P. J.,
Van Obberghen, E.,
and Le Marchand-Brustel, Y.
(1997)
Endocrinology
138,
2005-2010[Abstract/Free Full Text]
|
| 27.
|
Summers, S. A.,
Lipfert, L.,
and Birnbaum, M. J.
(1998)
Biochem. Biophys. Res. Commun.
246,
76-81[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Sun, X. J.,
Rothenberg, P.,
Kahn, C. R.,
Backer, J. M.,
Araki, E.,
Wilden, P. A.,
Cahill, D. A.,
Goldstein, B. J.,
and White, M. F.
(1991)
Nature
352,
73-77[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Kamohara, S.,
Hayashi, H.,
Todaka, M.,
Kanai, F.,
Ishii, K.,
Imanaka, T.,
Escobedo, J. A.,
Williams, L. T.,
and Ebina, Y.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
1077-1081[Abstract/Free Full Text]
|
| 30.
|
Quon, M. J.,
Chen, H.,
Lin, C. H.,
Zhou, L.,
Ing, B. L.,
Zarnowski, M. J.,
Klinghoffer, R.,
Kazlauskas, A.,
Cushman, S. W.,
and Taylor, S. I.
(1996)
Biochem. Biophys. Res. Commun.
226,
587-594[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Ricort, J.-M.,
Tanti, J.-F.,
Van Obberghen, E.,
and Le Marchand-Brustel, Y.
(1997)
J. Biol. Chem.
272,
19814-19818[Abstract/Free Full Text]
|
| 32.
|
Sharma, P. M.,
Egawa, K.,
Huang, Y.,
Martin, J. L.,
Huvar, I.,
Boss, G. R.,
and Olefsky, J. M.
(1998)
J. Biol. Chem.
273,
18528-18537[Abstract/Free Full Text]
|
| 33.
|
Altomare, D. A.,
Lyons, G. E.,
Mistsuuchi, Y.,
Cheng, J. Q.,
and Testa, J. R.
(1998)
Oncogene
16,
2407-2411[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Ikeda, S.,
Kishida, S.,
Yamamoto, H.,
Murai, H.,
Koyama, S.,
and Kikuchi, A.
(1998)
EMBO J.
17,
1371-1384[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Cross, D. A.,
Watt, P. W.,
Shaw, M.,
van der Kaay, J.,
Downes, C. P.,
Holder, J. C.,
and Cohen, P.
(1997)
FEBS Lett.
406,
211-215[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Gingras, A.,
Kennedy, S. G.,
O'Leary, M. A.,
Sonenberg, N.,
and Hay, N.
(1998)
Genes Dev.
12,
502-513[Abstract/Free Full Text]
|
| 37.
|
Klippel, A.,
Reinhard, C.,
Kavanaugh, W. M.,
Apell, G.,
Escobedo, M. A.,
and Williams, L. T.
(1996)
Mol. Cell. Biol.
16,
4117-4127[Abstract]
|
| 38.
|
Staal, S. P.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
5034-5037[Abstract/Free Full Text]
|
| 39.
|
Cheng, J. Q.,
Godwin, A. K.,
Bellacosa, A.,
Taguchi, T.,
Franke, T. F.,
Hamilton, T. C.,
Tsichlis, P. N.,
and Testa, J. R.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
9267-9271[Abstract/Free Full Text]
|
| 40.
|
van Weeren, P. C.,
de Bruyn, K. M. T.,
de Vries-Smits, A. M. M.,
van Lint, J.,
and Burgering, B. M. Th.
(1998)
J. Biol. Chem.
273,
13150-13156[Abstract/Free Full Text]
|
| 41.
|
Kitamura, T.,
Ogawa, W.,
Sakaue, H.,
Hino, Y.,
Kuroda, S.,
Takata, M.,
Matsumoto, M.,
Maeda, T.,
Konishi, H.,
Kikkawa, U.,
and Kasuga, M.
(1998)
Mol. Cell. Biol.
18,
3708-3717[Abstract/Free Full Text]
|
| 42.
|
Dudek, H.,
Datta, S. R.,
Franke, T. F.,
Birnbaum, M. J.,
Yao, R.,
Cooper, G. M.,
Segal, R. A.,
Kaplan, D. R.,
and Greenberg, M. E.
(1997)
Science
275,
661-665[Abstract/Free Full Text]
|
| 43.
|
Meier, R.,
Alessi, D. R.,
Cron, P.,
Andjelkovic, M.,
and Hemmings, B. A.
(1997)
J. Chem. Biol.
272,
30491-30497[Abstract/Free Full Text]
|
| 44.
|
Cong, L.-N.,
Chen, H.,
Li, Y.,
Zhou, L.,
McGibbon, M.,
Taylor, S.,
and Quon, M.
(1997)
Mol. Endocrinol.
11,
1881-1890[Abstract/Free Full Text]
|
| 45.
|
Summers, S. A.,
Garza, L. A.,
Zhou, H.,
and Birnbaum, M. J.
(1998)
Mol. Cell. Biol.
18,
5457-5464[Abstract/Free Full Text]
|
| 46.
|
Downward, J.
(1998)
Science
279,
673-674[Free Full Text]
|
| 47.
|
Clark, S. F.,
Martin, S.,
Carozzi, A. J.,
Hill, M. M.,
and James, D. E.
(1998)
J. Cell Biol.
140,
1211-1225[Abstract/Free Full Text]
|
| 48.
|
Jiang, T.,
Sweeney, G.,
Rudolf, M. T.,
Klip, A.,
Traynor-Kaplan, A.,
and Tsien, R. Y.
(1998)
J. Biol. Chem.
273,
11017-11024 |